Raptiva - Efalizumab - Dosage - Side Effects - Interactions - Warnings
Update: On April 8, 2009, Genentech, Inc. announced a phased voluntary withdrawal of the psoriasis drug Raptiva (efalizumab) from the U.S. market based on the association of Raptiva with an increased risk of progressive multifocal leukoencephalopathy (PML), a rare and usually fatal disease of the central nervous system.
Raptiva (Efalizumab) is a subcutaneous injection used to treat adult patients with moderate to severe plaque psoriasis whose psoriasis is appropriate for treatment with whole body (systemic therapy) or phototherapy.
Patient education for Raptiva / efalizumab injection.
03/28/2004, Study results show Raptiva (efalizumab) did not show statistical significance in improving symptoms of psoriatic arthritis by at least 20 percent.
05/13/2003, Genentech and Xoma stop development of the drug Raptiva (efalizumab) for rheumatoid arthritis.
06/20/2005, FDA adds new warnings on the Genentech psoriasis drug Raptiva (efalizumab) following reports of four cases of hemolytic anemia diagnosed four to six months after patients started on the monoclonal antibody, from FDA (pdf).
Patient information for Raptiva (Efalizumab), from Raptiva.com.
